volume 302, issue 9, PG1035-G1042 2012
DOI: 10.1152/ajpgi.00258.2011
View full text
|
|
Share

Abstract: Cystic fibrosis liver disease (CFLD) is treated with ursodeoxycholate (UDCA). Our aim was to evaluate, in cystic fibrosis transmembrane regulator knockout (Cftr(-/-)) mice and wild-type controls, whether the supposed therapeutic action of UDCA is mediated via choleretic activity or effects on bile salt metabolism. Cftr(-/-) mice and controls, under general anesthesia, were intravenously infused with tauroursodeoxycholate (TUDCA) in increasing dosage or were fed either standard or UDCA-enriched chow (0.5% wt/wt…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
8
1

Publication Types

Select...

Relationship

0
0

Authors

Journals